Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced esophageal squamous cell carcinoma
jRCT2080224669Phase 3Completed
- Sponsor
- BeiGene
- Start
- May 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial in Esophageal Squamous Cell Carcinoma (ESCC) comparing Tislelizumab + chemotherapy with Placebo + chemotherapy (2 arms). Primary endpoint: overall survival. Started May 2019; status: completed.
02
Drugs
tislelizumab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on jRCT2080224669.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224669.